Citigroup
RXRX icon

Citigroup’s Recursion Pharmaceuticals RXRX Stock Holding History

Citigroup’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Buy
+90,000
New +$300K ﹤0.01% 4096
2026
Q1 		– Sell
-30,000
Closed -$123K – 6332
2025
Q4 		$123K Buy
+30,000
New +$149K ﹤0.01% 4233
2025
Q1 		– Sell
-22,100
Closed -$149K – 5910
2024
Q4 		$149K Buy
+22,100
New +$149K ﹤0.01% 4615

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's RXRX Position: Q2 2026 in Review

Citigroup increased its Recursion Pharmaceuticals (RXRX) stake by 373% in Q2 2026, buying an estimated $2.27M and bringing the position to 864,403 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Citigroup first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $7.99M in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Citigroup held 864,403 shares of Recursion Pharmaceuticals worth $3.17M as of Q2 2026.
  • Citigroup bought 681,793 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2549 holding.
  • Citigroup first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Citigroup's Recursion Pharmaceuticals position peaked at $7.99M in Q1 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.